-
2024-515557-22-00
6
2022-10-01
Juvenile Idiopathic Arthritis
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2024-514630-21-00
4
2022-08-11
HER2 positive (HER2+), Hormone Receptor positive (HR+) Early-stage Bre
-
2023-505255-51-00
5
2022-08-08
Herpes Zoster
-
2023-509260-25-00
5
2022-07-12
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Canc
-
2023-505974-14-00
5
2022-06-23
Multiple Sclerosis (MS)
-
2024-510800-35-00
5
2022-06-17
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2023-509943-28-00
5
2022-05-18
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (
-
2023-507468-38-00
4
2022-04-22
Myelofibrosis
-
2024-514466-38-00
5
2022-04-19
Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
-
2024-512745-16-00
5
2022-04-13
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
-
2023-506761-65-00
10
2022-04-08
Spinal Muscular Atrophy (SMA)
-
2023-504597-37-00
5
2022-03-25
Focal segmental glomerulosclerosis
-
2024-511633-35-00
4
2022-03-21
Mantle cell lymphoma
-
2023-510432-36-00
4
2022-03-01
Acute Myeloid Leukemia with NPM1 mutation
-
2023-503640-14-00
5
2022-02-17
Newly diagnosed Philadelphia-negative B-cell precursor Acute Lymphobla
-
2023-503868-16-00
5
2022-02-14
Small-Cell Lung Cancer (SCLC)
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2023-504884-17-00
5
2022-02-04
Proteinuria
-
2024-518304-53-00
5
2022-02-02
Relapsed or Refractory Multiple Myeloma (RRMM)
-
2024-511492-15-00
5
2021-12-09
Duchenne Muscular Dystrophy
-
2023-510241-16-00
4
2021-12-03
Acute Myeloid Leukemia secondary to myeloproliferative neoplasms
-
2024-511636-27-00
5
2021-12-01
Follicular Lymphoma
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer